Arzerra (ofatumumab) - Novartis, Genmab
Ofatumumab in Treatment-Refractory¬ Narcolepsy Type 1 (clinicaltrials.gov) - Oct 14, 2026 - P1/2 | N=20 | Recruiting | Sponsor: Xijing Hospital 
New P1/2 trial • Narcolepsy • Sleep Disorder
http://clinicaltrials.gov/ct2/show/NCT07871006
 
Oct 14, 2026
 
Prev Next